Integrating Candidemia trial Data and Infrastructure to define New clinical trial Endpoints

Candi-NET

Candida is usually harmless in the gut, but can cause deadly bloodstream infections in hospitals with a 40% death rate. Rising resistance to antifungals necessitates new approaches.

Aim

This project aims to develop reliable biomarkers to improve treatment predictions and outcomes for antifungal-resistant Candida infections.

Method

The researchers utilise data from 4 European and South African trials involving around 700 patients. Through novel lab techniques, including genomics and machine learning, they will develop the biomarkers. Led by expert clinicians and researchers, they establish an international network for standardized data integration.